GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE288nnn/GSE288031/primaryOK200TranscriptomicsHomo sapiensExpression profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288031GEOGSEfalseGene expression profiling of 22Rv1 cells treated with a CDK9 degrader, Compound 45 (D45)As one of the serine/threonine protein kinase family members, Cyclin-dependent kinase 9 (CDK9) functions as a critical regulator of transcription. Its overexpression has been observed in various cancers, including prostate cancer, positioning it as a potential therapeutic target. D45, a newly developed small molecular CDK9 degrader, has been shown to significantly inhibit the growth of triple-negative breast cancer cells. Currently, we carried out a study to explore the role of CDK9 in castration-resistant prostate cancer (CRPC). Hence, human CRPC 22Rv1 cells were treated with small molecule compound, D45, targeting CDK9, followed by RNA-sequencing.2026/06/27GSE288031GSM8757700GSM8757699GSM8757702GSM875770129480288031Homo sapiens